| |
|
500,000 patients suffer from heart valve disease
Currently, some half a million patients suffer from heart valve disease worldwide and it is expected that by 2010 the number of patients will exceed 600,000. The cardiovascular market worldwide is estimated at US$ 20 billion, equally shared between the US, Europe and all other markets. Of this, the heart valve market represents US$ 1 billion.
The US heart valve disease market was valued at $557 million in 2004 and is estimated to reach $911 million in 2010. 2004 sales of mechanical and biological valves constitute more than 80%, representing about $450 million. 93,000 valves were implanted in 2004, biological valves accounting for more than 80% of the caseloads and mechanical valves for the remaining 20%.
Outside the United States, mechanical valves are primarily used and account for 70% of the implanted products while biological prostheses are used in 30% of the caseloads.
The market outside the United States (OUS) was valued at $537 million in 2004 and is estimated to reach $880 million in 2010 with a compound annual growth rate of 8.6%. Nowadays, 80% of the market is concentrated in Europe and Japan but it is estimated that in the future the highest growth will come from countries in South East Asia and from China.
|
